Finance Watch: Another VC Mega-Round As Flare Raises $123m Series B
Lead Program Moves Into Clinic Two Years After Series A
Private Company Edition: Flare Therapeutics, targeting transcription factors to discover precision medicines, had big pharma backing for its second venture capital financing. Also, Mediar closed a $10m series A round, Switch launched with $52m and EpiBiologics raised a $50m series A round.
